arrow
M

Mariasanta Napolitano

University of Palermo
H指数:29
被引数:2,507

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy

成人原发免疫性血小板减少症患者皮下注射治疗的实际经验:一项对意大利患者和临床医生的双横断面调查研究

2026-08-260
PRE
Safety of red blood cell transfusion despite serologic incompatibility in autoimmune hemolytic anemia: A real-world multicenter study

尽管存在血清学不相容性,自身免疫性溶血性贫血患者输注红细胞的 safety:一项真实世界多中心研究

2026-07-230
OA
Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study

临床异质性与获得性PRCA的结局:一项多中心欧洲研究

2026-05-280
OAAI
Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma

利妥昔单抗治疗血液学相关自身免疫性疾病或非霍奇金淋巴瘤患者的感染发生率

2026-05-090
OAAI
Integrating Clinical, Functional, and Patient-Reported Outcomes in Haemophilia Care: A Delphi-Based Consensus on a New Monitoring Tool

整合临床、功能及患者报告结局在血友病护理中的应用:基于德尔菲法的关于新监测工具的共识

2026-04-060
OAAI
Inflammatory Biomarkers for Thrombotic Risk Assessment in Multiple Myeloma Patients on IMiD/aCD38-Based Regimens: Insights from a Prospective Observational Study

基于IMiD/aCD38方案的多发性骨髓瘤患者血栓风险评估的炎症生物标志物:一项前瞻性观察研究的见解

2025-10-310
OAAI
Management of Pregnancy, Delivery, and Postpartum in Italian Carriers and Women With Haemophilia A and B

意大利携带者及血友病A和B女性患者的妊娠、分娩及产后管理

2025-07-290
PRE
Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study
2025-02-010
OAAI
Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION)
2024-12-010
OAAI
Management and Outcomes of Pregnancy and Childbirth in Known and Unknown Hemophilia Carriers: 10 Years Retrospective Evaluation from Southern Italy

已知和未知血友病携带者妊娠与分娩的管理及结局:意大利南部10年回顾性评估

BLOOD
IF23.1
2024-11-050
PRE
Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life

Efmorocog alfa的药代动力学通过两室模型突出了具有双相衰变,长平均停留时间和 β 半衰期的血友病A患者

2024-08-230
OAAI